Combination of epidermal growth factor receptor mutation and the presence of high-grade patterns is associated with recurrence in resected stage I lung adenocarcinoma

被引:3
|
作者
Kondo, Yasuto [1 ,2 ]
Ichinose, Junji [1 ]
Ninomiya, Hironori [3 ,4 ]
Hashimoto, Kohei [1 ]
Matsuura, Yosuke [1 ]
Nakao, Masayuki [1 ]
Ishikawa, Yuichi [3 ,4 ,5 ]
Okumura, Sakae [1 ]
Satoh, Yukitoshi [2 ]
Mun, Mingyon [1 ]
机构
[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Thorac Surg Oncol, Tokyo, Japan
[2] Kitasato Univ, Sch Med, Dept Thorac Surg, Sagamihara, Kanagawa, Japan
[3] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Pathol, Tokyo, Japan
[4] Japanese Fdn Canc Res, Canc Inst, Div Pathol, Tokyo, Japan
[5] Int Univ Hlth & Welf, Mita Hosp, Dept Pathol, Tokyo, Japan
关键词
Lung adenocarcinoma; Epidermal growth factor receptor; Recurrence; Surgery; Histological subtype; LYMPH-NODE METASTASIS; MICROPAPILLARY PATTERN; HISTOLOGIC SUBTYPE; EGFR; IMPACT; CLASSIFICATION; CANCER; LOBECTOMY; CISPLATIN; REVISION;
D O I
10.1093/icvts/ivac062
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES: This study aimed to evaluate the prognostic impact of the combination of epidermal growth factor receptor (EGFR) mutation and the presence of high-grade patterns (solid or micropapillary component) in resected stage I lung adenocarcinoma. METHODS: Patients who underwent curative resection for pathological stage I lung adenocarcinoma and EGFR mutation analysis were included in this study. The impact of the combination of EGFR mutation and the presence of >5% high-grade patterns on recurrence-free survival (RFS) was retrospectively analysed using Cox proportional hazards model and propensity score-matched analysis. RESULTS: Among the included 721 patients, EGFR mutations were positive in 380 (52.7%). In the EGFR-mutated group, cases with highgrade patterns showed poorer RFS than those without (5-year RFS, 77.7% vs 92.5%, P < 0.001), whereas there were no significant prognostic differences in the EGFR wild-type group (5-year RFS, 89.8% vs 88.2%, P = 0.807). Multivariable analyses revealed that the combination of EGFR mutations and the presence of high-grade patterns was associated with poor RFS (hazard ratio = 1.655, P = 0.035). Furthermore, EGFR mutation was associated with poor RFS in the group with high-grade patterns (hazard ratio = 2.108, P = 0.008). After propensity score matching, EGFR-mutated cases with high-grade patterns showed poorer RFS (P = 0.028). CONCLUSIONS: The combination of EGFR mutation and the presence of high-grade patterns was associated with recurrence in resected stage I lung adenocarcinoma. Histological subtypes, including minor components, should be considered when evaluating the risk of recurrence in patients with EGFR-mutated lung adenocarcinoma.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Prognostic outcomes and recurrence patterns in resected stage I lung adenocarcinoma harbouring atypical epidermal growth factor receptor mutations
    Chen, Tao
    Wen, Jialiang
    Li, Yingze
    Deng, Jiajun
    Zhong, Yifan
    Hou, Likun
    She, Yunlang
    Xie, Dong
    Chen, Chang
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2024, 65 (01)
  • [2] Epidermal Growth Factor Receptor Mutation Status in Stage I Lung Adenocarcinoma with Different Image Patterns
    Hsu, Kuo-Hsuan
    Chen, Kun-Chieh
    Yang, Tsung-Ying
    Yeh, Yi-Chen
    Chou, Teh-Ying
    Chen, Hsuan-Yu
    Tsai, Chi-Ren
    Chen, Chih-Yi
    Hsu, Chung-Ping
    Hsia, Jiun-Yi
    Chuang, Cheng-Yen
    Tsai, Ying-Huang
    Chen, Kuan-Yu
    Huang, Ming-Shyan
    Su, Wu-Chou
    Chen, Yuh-Min
    Hsiung, Chao A.
    Chang, Gee-Chen
    Chen, Chien-Jen
    Yang, Pan-Chyr
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : 1066 - 1072
  • [3] Epidermal Growth Factor Receptor Mutation as a Risk Factor for Recurrence in Lung Adenocarcinoma
    Hayasaka, Kazuki
    Shiono, Satoshi
    Matsumura, Yuki
    Yanagawa, Naoki
    Suzuki, Hiroyuki
    Abe, Jiro
    Sagawa, Motoyasu
    Sakurada, Akira
    Katahira, Masato
    Takahashi, Satomi
    Endoh, Makoto
    Okada, Yoshinori
    ANNALS OF THORACIC SURGERY, 2018, 105 (06): : 1648 - 1654
  • [4] Risk Factors for Recurrence of Stage I Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma
    Kamigaichi, Atsushi
    Mimae, Takahiro
    Tsubokawa, Norifumi
    Miyata, Yoshihiro
    Adachi, Hiroyuki
    Shimada, Yoshihisa
    Ito, Hiroyuki
    Ikeda, Norihiko
    Okada, Morihito
    ANNALS OF THORACIC SURGERY, 2024, 117 (04): : 743 - 751
  • [5] The Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Clinical Stage I Lung Adenocarcinoma
    Yang, Fujun
    Sun, Ke
    Li, Fei
    Li, Xiang
    Shi, Jinghan
    Sun, Xiwen
    Hong, Yong
    Jiang, Gening
    Zhu, Yuming
    Song, Xiao
    ANNALS OF THORACIC SURGERY, 2024, 117 (06): : 1111 - 1119
  • [6] Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma
    Deng, Chaoqiang
    Zhang, Yang
    Ma, Zelin
    Fu, Fangqiu
    Deng, Lin
    Li, Yuan
    Chen, Haiquan
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2021, 162 (03): : 664 - +
  • [7] Presence of Epidermal Growth Factor Receptor (EGFR) Mutation Predicts a Lower Grade Morphology and Lower AJCC Stage in Patients with Lung Adenocarcinoma
    Villa, C.
    Yeldandi, A.
    Nayar, R.
    Cagle, P.
    Raparia, K.
    LABORATORY INVESTIGATION, 2012, 92 : 491A - 492A
  • [8] Presence of Epidermal Growth Factor Receptor (EGFR) Mutation Predicts a Lower Grade Morphology and Lower AJCC Stage in Patients with Lung Adenocarcinoma
    Villa, C.
    Yeldandi, A.
    Nayar, P.
    Cagle, P.
    Raparia, K.
    MODERN PATHOLOGY, 2012, 25 : 491A - 492A
  • [9] Clinicopathological Features and Significance of Epidermal Growth Factor Receptor Mutation in Surgically Resected Early-Stage Lung Adenocarcinoma
    Lu, Chao-Wen
    Lin, Mong-Wei
    Chiang, Xu-Heng
    Hsu, Hsao-Hsun
    Hsieh, Min-Shu
    Chen, Jin-Shing
    DIAGNOSTICS, 2023, 13 (03)
  • [10] Computed tomography and clinical features associated with epidermal growth factor receptor mutation status in stage I/II lung adenocarcinoma
    Zou, Jiawei
    Lv, Tangfeng
    Zhu, Suhua
    Lu, Zhenfeng
    Shen, Qin
    Xia, Leilei
    Wu, Jie
    Song, Yong
    Liu, Hongbing
    THORACIC CANCER, 2017, 8 (03) : 260 - 270